Trial Profile
A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Intetumumab (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Centocor
- 09 May 2012 New source identified and integrated (German Clinical Trials Register record, DRKS00003882).
- 24 Feb 2010 Actual end date (November 2009) added as reported by ClinicalTrials.gov.
- 24 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.